Resolvin D1 modulates periodontal ligament fibroblast function.
aspirin-triggered resolvin D1
cytokine
fibroblast
inflammation
periodontal disease
regeneration
Journal
Journal of periodontology
ISSN: 1943-3670
Titre abrégé: J Periodontol
Pays: United States
ID NLM: 8000345
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
05
11
2022
received:
07
09
2022
accepted:
13
11
2022
pmc-release:
01
05
2024
medline:
24
5
2023
pubmed:
24
11
2022
entrez:
23
11
2022
Statut:
ppublish
Résumé
The resolution of inflammation is an active process mediated by specialized lipid mediators called lipoxins and resolvins. Periodontal ligament fibroblasts (PDLFs) play a significant role in periodontal regeneration. The purpose of the current study was to determine the impact of resolvin D1 (RvD1) on human PDLF cell wound healing and proliferation, receptor expression (G-protein-coupled receptor 32 [GPR32] and formyl peptide receptor 2 [ALX/FPR2]), and cytokine expression and release. PDLFs were stimulated with interleukin-1β (IL-1β) (500 pg/ml) with and without RvD1 (100 nM). RvD1 receptor expression was determined by quantitative real-time polymerase chain reaction (qPCR), immunofluorescence microscopy, and fluorescence-activated cell sorting. Wound closure was measured by a scratch assay, and proliferation was determined by bromodeoxyuridine incorporation. Interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant protein-1, cyclooxygenase-2, matrix metalloproteinases-1, -2, and -3 (MMP-1, -2, and -3), tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and -2), prostaglandin E2, and osteoprotegerin (OPG) gene expression and production were measured using qPCR and Western blotting, multiplex immunoassay, and enzyme-linked immunosorbent assay. PDLF expressed GPR32 and ALX/FPR2. RvD1 reversed IL-1β-induced inhibition of wound healing and proliferation of PDLF. IL-1β also induced the production of proinflammatory cytokines and MMPs. This effect was reversed by RvD1. RvD1 reversed IL-1β-induced inhibition of TIMP-1, TIMP-2, and OPG. The data suggested that RvD1 has a pro-wound healing, proliferative, and anti-inflammatory impact on the PDLF that favors periodontal regeneration.
Sections du résumé
BACKGROUND
The resolution of inflammation is an active process mediated by specialized lipid mediators called lipoxins and resolvins. Periodontal ligament fibroblasts (PDLFs) play a significant role in periodontal regeneration. The purpose of the current study was to determine the impact of resolvin D1 (RvD1) on human PDLF cell wound healing and proliferation, receptor expression (G-protein-coupled receptor 32 [GPR32] and formyl peptide receptor 2 [ALX/FPR2]), and cytokine expression and release.
METHODS
PDLFs were stimulated with interleukin-1β (IL-1β) (500 pg/ml) with and without RvD1 (100 nM). RvD1 receptor expression was determined by quantitative real-time polymerase chain reaction (qPCR), immunofluorescence microscopy, and fluorescence-activated cell sorting. Wound closure was measured by a scratch assay, and proliferation was determined by bromodeoxyuridine incorporation. Interleukin-6 (IL-6), interleukin-8 (IL-8), monocyte chemoattractant protein-1, cyclooxygenase-2, matrix metalloproteinases-1, -2, and -3 (MMP-1, -2, and -3), tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1 and -2), prostaglandin E2, and osteoprotegerin (OPG) gene expression and production were measured using qPCR and Western blotting, multiplex immunoassay, and enzyme-linked immunosorbent assay.
RESULTS
PDLF expressed GPR32 and ALX/FPR2. RvD1 reversed IL-1β-induced inhibition of wound healing and proliferation of PDLF. IL-1β also induced the production of proinflammatory cytokines and MMPs. This effect was reversed by RvD1. RvD1 reversed IL-1β-induced inhibition of TIMP-1, TIMP-2, and OPG.
CONCLUSION
The data suggested that RvD1 has a pro-wound healing, proliferative, and anti-inflammatory impact on the PDLF that favors periodontal regeneration.
Identifiants
pubmed: 36416879
doi: 10.1002/JPER.22-0462
pmc: PMC10354588
mid: NIHMS1913748
doi:
Substances chimiques
resolvin D1
0
Tissue Inhibitor of Metalloproteinase-1
0
Docosahexaenoic Acids
25167-62-8
Cytokines
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
683-693Subventions
Organisme : NIDCR NIH HHS
ID : R01 DE025020
Pays : United States
Informations de copyright
© 2022 American Academy of Periodontology.
Références
J Clin Invest. 2021 Dec 15;131(24):
pubmed: 34699386
Am J Pathol. 1997 Aug;151(2):317-22
pubmed: 9250144
J Periodontal Res. 1998 May;33(4):212-25
pubmed: 9689617
J Exp Med. 1994 Jul 1;180(1):253-60
pubmed: 8006586
J Periodontol. 2013 Dec;84(12):1838-46
pubmed: 23398023
Proc Natl Acad Sci U S A. 2010 Jan 26;107(4):1660-5
pubmed: 20080636
Periodontol 2000. 2009;51:208-19
pubmed: 19878476
J Clin Immunol. 2003 May;23(3):147-61
pubmed: 12797537
Biochem Biophys Res Commun. 2015 Sep 4;464(4):1072-1077
pubmed: 26188508
J Immunol. 2013 Jan 15;190(2):689-94
pubmed: 23241890
J Periodontol. 1976 May;47(5):256-60
pubmed: 775048
J Dent Res. 1990 Aug;69(8):1456-62
pubmed: 2117029
Front Immunol. 2021 May 19;12:668760
pubmed: 34093566
J Periodontal Res. 1995 Jan;30(1):23-33
pubmed: 7722844
J Dent Res. 2015 Jan;94(1):148-56
pubmed: 25389003
Prostaglandins Leukot Essent Fatty Acids. 2005 Sep-Oct;73(3-4):179-87
pubmed: 15978792
Periodontol 2000. 2014 Feb;64(1):57-80
pubmed: 24320956
J Biol Chem. 2000 Aug 25;275(34):26225-32
pubmed: 10843992
Bone. 2005 Feb;36(2):267-75
pubmed: 15780952
Am J Pathol. 2001 Jun;158(6):1969-73
pubmed: 11395373
Am J Physiol Cell Physiol. 2013 Sep 15;305(6):C673-9
pubmed: 23864609
FASEB J. 2006 Feb;20(2):401-3
pubmed: 16373400
J Tissue Viability. 2011 Nov;20(4):108-20
pubmed: 19995679
Infect Immun. 1999 Jun;67(6):2804-9
pubmed: 10338484
J Biol Chem. 1993 Dec 5;268(34):25395-401
pubmed: 8244972
Oral Microbiol Immunol. 2006 Feb;21(1):12-20
pubmed: 16390336
Arch Oral Biol. 1988;33(4):237-43
pubmed: 3261162
J Immunol. 2007 Nov 15;179(10):7021-9
pubmed: 17982093
J Invest Dermatol. 2007 Mar;127(3):514-25
pubmed: 17299434
J Exp Med. 2002 Oct 21;196(8):1025-37
pubmed: 12391014
Clin Oral Investig. 2012 Feb;16(1):275-83
pubmed: 21225299
J Dent Res. 2007 Apr;86(4):306-19
pubmed: 17384024
J Periodontol. 2001 Nov;72(11):1624-8
pubmed: 11759876
PLoS One. 2013;8(3):e58258
pubmed: 23484005
Periodontol 2000. 1993 Feb;1:16-25
pubmed: 9673205
J Oral Sci. 2008 Sep;50(3):247-52
pubmed: 18818458
Mol Biol Rep. 2021 Jan;48(1):57-66
pubmed: 33459958
J Biol Chem. 2000 Dec 15;275(50):39012-7
pubmed: 10960471
Exp Hematol. 2006 Oct;34(10):1289-95
pubmed: 16982321
Blood. 2000 Oct 15;96(8):2887-94
pubmed: 11023526
J Periodontal Res. 2003 Jun;38(3):247-54
pubmed: 12753361